Yimin He

Director Alliance Management, Corporate Development @ argenx

About

Professional with years of experience in Consultancy and Biotech Industry in positions related to Corporate Strategy, Market Access & Business Development across Europe and the US in multiple therapeutic areas, including oncology and orphan disease

Country

Germany

City

Berlin

Industry

Pharmaceuticals

Skill

Portfolio Management, Strategy, Analytical Skills, Corporate Development, Biotechnology Industry, Corporate Strategy, Due Diligence, Market Entry, Corporate Finance, Asset Evaluation, Commercial, Product Launch, Acquisition Integration, Human Resources (HR), Strategic Planning, Corporate Governance, Mergers & Acquisitions (M&A), Business Modeling, Consulting, Market Research

Experience

Director Alliance Management, Corporate Development

argenx

2026-3 - Present · 6 mos

Germany

Consultant, Corporate Development & Strategy

argenx

2025-7 - 2026-3 · 9 mos

Germany

Director, Strategy & Business Development

MorphoSys

2024-3 - 2025-6 · 1 yr 4 mos

Germany

Associate Director, Corporate Strategy & Business Development

MorphoSys

2022-10 - 2024-3 · 1 yr 6 mos

Germany

Sr. Manager, European Market Access & Pricing

STADA Group

2021-10 - 2022-10 · 1 yr 1 mo

Frankfurt Rhine-Main Metropolitan Area

- Evaluated and planned early access program for orphan drug (Kinpeygo, IgAN) - Coordinated and supported orphan product launch (Kinpeygo) in Europe incl. launching sequencing optimisation and oversaw HTA dossiers and health economic model (CEA, BIA) - Lead pricing & market access evaluation for specialty in-license M&A deals - Monitored & analyzed health policy regulations, especially related to specialty products incl. biosimilar

Global Market Access & BD Manager

Adrenomed AG

2020-3 - 2021-10 · 1 yr 8 mos

Berlin, Germany

Report to: CBO Responsible: Pricing & Market access; Asset evaluation and Business Development in China Global Pricing & Market Access in the Europe, the US and Asia: - Build pricing & market access function from scratch incl. education material development - Lead early global pricing project to understand price potential of Adrecizumab and reimbursement landscape for sepsis & shock (In-patient product) in Europe, the US and Asia (Japan & China) - Lead HTA and health outcomes strategy development and payer value demonstration incl. coordination external vendors for early evidence generation - Participated in the pivotal trial protocol - added health economic relevant endpoints Asset Evaluation: - Conducted systematic review of epidemiology of sepsis and septic shock in EU5, the US, China and Japan -Responsible for asset forecasting (NPV) and evaluation: conducted country-level epidemiology study, interacted early with payers (hospital P&Ts) and developed financial model Business Development: - In charge of reaching out and interaction with potential Chinese partners - Developed "strawman" termsheet

Strategy Consultant, Life Science

Accenture

2017-10 - 2019-12 · 2 yrs 3 mos

Paris, France

Strategy consulting in Bionest Partners, Part of Acceunture with a focus on life sciences and healthcare in the following therapy areas: oncology, metabolic disease and autoimmune disease Expertise: - Supports US biotechnology companies develop EU Go-To-Market strategies - Assignment includes opportunity assessment (market landscape, competition map out, pricing evaluation, forecasting and market access), organizational structure for EU implementation (HQ location, EU infrastructure and recruitment sequence) and financial analysis (P&L, NPV / IRR analysis) Other projects: - Business development strategy (search & scout, asset valuation) - Pricing Evaluation (launching sequencing) - Commercial strategy (franchise / product strategy, organization design, competitive simulations) - Strategic / commercial due diligences